title: Intravenous (IV) bortezomib infusion after non-response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: are some patients more sensitive to IV bortezomib?
authors.affiliation: Division of Haematology, University of Siena, Siena, Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Gozzetti
authors.affiliation: Division of Haematology, University of Siena, Siena, Italy.
authors.forename: Veronica
authors.initials: V
authors.lastname: Candi
authors.affiliation: Division of Haematology, University of Siena, Siena, Italy.
authors.forename: Corrado
authors.initials: C
authors.lastname: Zuanelli Brambilla
authors.affiliation: Division of Haematology, University of Siena, Siena, Italy.
authors.forename: Giulia
authors.initials: G
authors.lastname: Papini
authors.affiliation: Division of Haematology, University of Siena, Siena, Italy.
authors.forename: Monica
authors.initials: M
authors.lastname: Bocchia
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000069286:Bortezomib / Q000008:administration & dosage*; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000069286:Bortezomib
keywords: multiple myeloma; resistance; subcutaneous bortezomib